PSAP and colorectal carcinoma: Researchers developed the SEC6 risk-scoring algorithm combining PSAP with IGFBP3, CD109, LTBP1, BMP1, and NPC2 expression to stratify patients and guide personalized treatment, confirming PSAP’s value in CRC prognosis and chemotherapy prediction [21] (Figure 6).